MX2020002968A - Moduladores selectivos de p2x3. - Google Patents

Moduladores selectivos de p2x3.

Info

Publication number
MX2020002968A
MX2020002968A MX2020002968A MX2020002968A MX2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A
Authority
MX
Mexico
Prior art keywords
selective
antagonist
modulators
receptor antagonism
warm
Prior art date
Application number
MX2020002968A
Other languages
English (en)
Inventor
Denis Garceau
Antonios Matzouranis
Roberto Bellini
Kemal Payza
Nathalie Chauret
Susan E Browne
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of MX2020002968A publication Critical patent/MX2020002968A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)

Abstract

En la presente se proporcionan métodos para el tratamiento para evitar la respuesta de pérdida de sabor mientras se trata a un paciente con tos crónica con un modulador selectivo P2X3.
MX2020002968A 2017-09-18 2018-09-14 Moduladores selectivos de p2x3. MX2020002968A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560077P 2017-09-18 2017-09-18
US15/936,316 US10111883B1 (en) 2017-09-18 2018-03-26 Selective P2X3 modulators
PCT/IB2018/001513 WO2019064079A2 (en) 2017-09-18 2018-09-14 SELECTIVE MODULATORS OF P2X3

Publications (1)

Publication Number Publication Date
MX2020002968A true MX2020002968A (es) 2020-08-17

Family

ID=63894683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002968A MX2020002968A (es) 2017-09-18 2018-09-14 Moduladores selectivos de p2x3.

Country Status (12)

Country Link
US (6) US10111883B1 (es)
EP (2) EP4331669A3 (es)
JP (1) JP7242681B2 (es)
KR (1) KR20200092938A (es)
CN (1) CN111601601A (es)
AU (1) AU2018342751B2 (es)
CA (1) CA3076150C (es)
ES (1) ES2969868T3 (es)
IL (2) IL303257A (es)
MX (1) MX2020002968A (es)
SG (1) SG11202002460QA (es)
WO (1) WO2019064079A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963702T3 (es) * 2018-10-05 2024-04-01 Shionogi & Co Medicina para tratar la tos crónica
WO2020074962A1 (en) * 2018-10-10 2020-04-16 Bellus Health Cough Inc. Treatment of pruritus with p2x3 antagonists
WO2020099923A1 (en) 2018-11-13 2020-05-22 Bellus Health Cough Inc. Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator
CN113272301B (zh) * 2018-12-29 2024-04-26 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用
CA3131312A1 (en) * 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN115413279A (zh) * 2020-02-14 2022-11-29 贝卢斯医疗咳嗽病公司 P2x3调节剂
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
US20230406850A1 (en) * 2020-06-29 2023-12-21 Wuhan Ll Science And Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
TW202214619A (zh) * 2020-08-13 2022-04-16 大陸商上海拓界生物醫藥科技有限公司 苯并咪唑類衍生物、其製備方法及醫藥用途
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2022258059A1 (zh) * 2021-06-10 2022-12-15 武汉朗来科技发展有限公司 一种药物组合物、制剂及其制备方法和应用
WO2023020156A1 (zh) * 2021-08-20 2023-02-23 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741245B (zh) 2009-11-18 2014-11-05 尼奥梅德研究院 苯并咪唑化合物及其用途
JP6373280B2 (ja) * 2013-01-31 2018-08-15 ネオメド・インスティチュート イミダゾピリジン化合物及びその使用
RU2650118C2 (ru) 2013-08-23 2018-04-09 Афферент Фармасьютикалз Инк. Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
EP3355889B1 (en) 2015-09-29 2023-02-15 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
WO2018064135A1 (en) * 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods

Also Published As

Publication number Publication date
CA3076150C (en) 2024-01-02
JP7242681B2 (ja) 2023-03-20
EP3684368A2 (en) 2020-07-29
WO2019064079A3 (en) 2019-05-16
CN111601601A (zh) 2020-08-28
SG11202002460QA (en) 2020-04-29
US20200230148A1 (en) 2020-07-23
US10111883B1 (en) 2018-10-30
US20210069201A1 (en) 2021-03-11
IL273348B2 (en) 2023-11-01
US20230248736A1 (en) 2023-08-10
EP3684368A4 (en) 2021-05-26
ES2969868T3 (es) 2024-05-23
CA3076150A1 (en) 2019-04-04
US20210322432A1 (en) 2021-10-21
AU2018342751A1 (en) 2020-04-23
EP4331669A3 (en) 2024-05-01
EP4331669A2 (en) 2024-03-06
IL303257A (en) 2023-07-01
WO2019064079A2 (en) 2019-04-04
IL273348A (en) 2020-05-31
EP3684368B8 (en) 2024-02-14
IL273348B1 (en) 2023-07-01
JP2020534355A (ja) 2020-11-26
US20220160724A1 (en) 2022-05-26
AU2018342751B2 (en) 2023-06-15
KR20200092938A (ko) 2020-08-04
EP3684368B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
MX2020002968A (es) Moduladores selectivos de p2x3.
MX2022009463A (es) Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
MX369770B (es) Compuestos agonistas triples de glucagón-glp-1-gip.
MX2018000278A (es) Terapia de receptores quimericos de puntos de control inmunitarios.
GB201709034D0 (en) Improvements in or relating to well abandonment
SA516370641B1 (ar) مركبات حلقية غير متجانسة وطرق لاستخدامها
WO2016094566A3 (en) Blood brain barrier receptor antibodies and methods of use
MX2023002379A (es) Proteinas de fusion de union a dr5 multivalentes y multiespecificas.
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EP2976338A4 (en) N- (2-CYANO-HETEROCYCLYL) PYRAZOLO-PYRIDONES AS INHIBITORS OF JANUS KINASE
HK1215573A1 (zh) 作為代謝型谷氨酸受體拮抗劑的乙炔基衍生物
TW201613884A (en) Selective NR2B antagonists
GB2580738B (en) Improvements in or relating to well abandonment
GB201713525D0 (en) Improvements in or relating to well abandonment
GB2574054B (en) Improvements in or relating to well abandonment
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale
GB2582745B (en) Improvements in or relating to well abandonment
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
GB201716096D0 (en) Improvements in or relating to well abandonment
GB2582553B (en) Improvements in or relating to well abandonment
GB2571207B (en) Intelligent, real-time response to changes in oilfield equilibrium
PL3494122T3 (pl) Podstawione rybonukleozydy heteropentadienopirolopirymidynowe do użytku terapeutycznego
GB201811289D0 (en) Improvements in or relating to well abandonment
GB201801991D0 (en) Improvements in or relating to well abandonment
PL3765475T3 (pl) Podstawione rybonukleozydy pirydopirolopirymidynowe do zastosowań terapeutycznych